Combined Associations of Glycoprotein Acetylation With Lipoprotein (a) and hs‐CRP (High‐Sensitivity C‐Reactive Protein) on Risk of Cardiovascular Disease in MESA
5 affiliations
- 1University of Southern California
- 2University of Minnesota School of Public Health
- 3University of Minnesota
- 4Labcorp
- 5University of California San Diego
Abstract
BACKGROUND: Higher plasma glycoprotein acetylation (GlycA) concentrations are associated with an increased risk for incident cardiovascular disease (CVD). We investigated the combined associations of GlycA with lipoprotein (a) (Lp[a]) and hs-CRP (high-sensitivity C-reactive protein) with incident CVD. METHODS: We followed 6676 MESA (Multi-Ethnic Study of Atherosclerosis) participants, aged 45 to 84 years, without baseline CVD. Lp(a), GlycA, and hs-CRP were evaluated categorically using standard cut points (Lp[a]: 50 mg/dL; GlycA: 400 μmol/L; hs-CRP: 2 mg/L). We used multivariable-adjusted Cox hazards models to evaluate individual and combined associations of these 3 biomarkers with incident CVD, coronary heart disease, and stroke. RESULTS: Compared with those with low GlycA and low Lp(a) levels, an increase in both incident CVD and coronary heart disease risk was observed for those participants with high levels of either or both of these biomarkers. Risk was highest for those with both high GlycA and high Lp(a) levels (CVD hazard ratio [HR]=1.55 [95% CI: 1.15-2.10) and coronary heart disease (HR=1.92 [95% CI, 1.33-2.77). A similar pattern was not observed for individuals with high levels of both GlycA and hs-CRP. Compared with participants with low levels of GlycA, Lp(a), and hs-CRP, those with high levels of all 3 biomarkers had a 1.98-fold higher CVD risk (95% CI, 1.39-2.82), a 2.23-fold higher coronary heart disease risk (95% CI, 1.45-3.44), and a 2.51-fold higher stroke risk (95% CI, 1.24-5.08). CONCLUSIONS: Routine assessment of GlycA in addition to Lp(a) and hs-CRP may help to identify individuals at particularly increased CVD risk who may benefit from more aggressive preventive therapies.
Related
- Lipoprotein and inflammatory glycoprotein profiles in women with polycystic ovary syndrome alone or in association with type 1 diabetes
- Cumulative average lipoprotein combined index-waist circumference and incident cardiovascular disease in Chinese middle-aged and older adults
- Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML)
- Small dense low-density lipoprotein cholesterol and risk of cardiovascular events in general adults: a systematic review and meta-analysis of prospective studies.
- Joint association of the cholesterol–high-density lipoprotein–glucose index and waist-to-height ratio with incident cardiovascular disease in a high-risk Chinese cohort
BibTeX
@article{garg2026combined,
title = {{Combined Associations of Glycoprotein Acetylation With Lipoprotein (a) and hs‐CRP (High‐Sensitivity C‐Reactive Protein) on Risk of Cardiovascular Disease in MESA}},
author = {Parveen K. Garg and Weihua Guan and Sarah Nomura and James D. Otvos and Margery A. Connelly and Harpreet S. Bhatia and Amy B. Karger and Michael Y. Tsai},
journal = {Journal of the American Heart Association},
year = {2026},
month = oct,
doi = {10.1161/jaha.125.048493},
url = {https://www.ahajournals.org/doi/10.1161/JAHA.125.048493},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Combined Associations of Glycoprotein Acetylation With Lipoprotein (a) and hs‐CRP (High‐Sensitivity C‐Reactive Protein) on Risk of Cardiovascular Disease in MESA
AU - Parveen K. Garg
AU - Weihua Guan
AU - Sarah Nomura
AU - James D. Otvos
AU - Margery A. Connelly
AU - Harpreet S. Bhatia
AU - Amy B. Karger
AU - Michael Y. Tsai
PY - 2026
DA - 2026/10/20
JO - Journal of the American Heart Association
DO - 10.1161/jaha.125.048493
UR - https://www.ahajournals.org/doi/10.1161/JAHA.125.048493
AB - BACKGROUND: Higher plasma glycoprotein acetylation (GlycA) concentrations are associated with an increased risk for incident cardiovascular disease (CVD). We investigated the combined associations of GlycA with lipoprotein (a) (Lp[a]) and hs-CRP (high-sensitivity C-reactive protein) with incident CVD. METHODS: We followed 6676 MESA (Multi-Ethnic Study of Atherosclerosis) participants, aged 45 to 84 years, without baseline CVD. Lp(a), GlycA, and hs-CRP were evaluated categorically using standard cut points (Lp[a]: 50 mg/dL; GlycA: 400 μmol/L; hs-CRP: 2 mg/L). We used multivariable-adjusted Cox hazards models to evaluate individual and combined associations of these 3 biomarkers with incident CVD, coronary heart disease, and stroke. RESULTS: Compared with those with low GlycA and low Lp(a) levels, an increase in both incident CVD and coronary heart disease risk was observed for those participants with high levels of either or both of these biomarkers. Risk was highest for those with both high GlycA and high Lp(a) levels (CVD hazard ratio [HR]=1.55 [95% CI: 1.15-2.10) and coronary heart disease (HR=1.92 [95% CI, 1.33-2.77). A similar pattern was not observed for individuals with high levels of both GlycA and hs-CRP. Compared with participants with low levels of GlycA, Lp(a), and hs-CRP, those with high levels of all 3 biomarkers had a 1.98-fold higher CVD risk (95% CI, 1.39-2.82), a 2.23-fold higher coronary heart disease risk (95% CI, 1.45-3.44), and a 2.51-fold higher stroke risk (95% CI, 1.24-5.08). CONCLUSIONS: Routine assessment of GlycA in addition to Lp(a) and hs-CRP may help to identify individuals at particularly increased CVD risk who may benefit from more aggressive preventive therapies.
SN - 2047-9980
ER -